Clinical TrialOct 29, 2026, 08:11 AM
Coherus Oncology: Tagmokitug Shows 75% ORR in First-Line ESCC Trial
AI Summary
Coherus Oncology announced interim clinical data from the TREGCHECK™ development program evaluating tagmokitug in combination with toripalimab. The data showed encouraging anti-tumor activity across multiple solid tumors, particularly in esophageal squamous cell carcinoma (ESCC). In first-line ESCC, the combination demonstrated a 75% confirmed overall response rate (cORR) irrespective of PD-L1 status, increasing to 89% post-data cutoff. Second-line ESCC also showed durable clinical benefit. The company plans to expand enrollment in ESCC cohorts based on these positive interim findings and a manageable safety profile.
Key Highlights
- First-line ESCC: 75% cORR (all comers), 100% cORR (PD-L1 positive) with tagmokitug + toripalimab + chemo.
- Post-data-cutoff cORR for first-line ESCC increased to 89% (8/9 evaluable patients).
- Second-line ESCC (700mg arm): 16.7% cORR and 5.5 months mPFS with tagmokitug + toripalimab.
- 2L Upper GI (700mg arm): 23.5% cORR in EAC patients with tagmokitug + toripalimab.
- Tagmokitug demonstrated a manageable safety profile across the TREGCHECK™ program.
- Coherus plans to expand enrollment in first-line and second-line ESCC cohorts.
Price Impact
More from CHRS